Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. SGMO
SGMO logo

SGMO

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

SGMO News

Sangamo Advances Gene Therapy Application for Fabry Disease

1d agoNewsfilter

Sangamo Reports Positive Data for Fabry Disease Treatment

Feb 04 2026NASDAQ.COM

Sangamo Therapeutics Shares Plunge Over 31%

Feb 03 2026Yahoo Finance

Sangamo Therapeutics Shares Plunge 28% After $25M Stock Offering

Feb 03 2026seekingalpha

Sangamo Therapeutics Announces Pricing of Stock Offering

Feb 03 2026Newsfilter

Sangamo Initiates BLA Submission for ST-920, Expected in Q2 2026

Dec 18 2025Globenewswire

Sangamo Initiates BLA Submission for ST-920, Expected Completion in Q2 2026

Dec 18 2025Newsfilter

Sangamo Receives FDA Fast Track Designation for ST-503 in Chronic Pain Treatment

Dec 02 2025Globenewswire

Sangamo Soars After FDA Awards Fast Track Designation to Neuropathic Pain Treatment

Dec 02 2025SeekingAlpha

Sangamo Receives FDA Acceptance for Gene Therapy BLA Submission

Nov 24 2025Newsfilter

FDA Approves Sangamo's Proposal for Rolling BLA Submission of Gene Therapy Candidate for Fabry Disease

Nov 21 2025NASDAQ.COM

Sangamo Shares Climb Following FDA's Acceptance of Gene Therapy Rolling Submission Request

Nov 21 2025SeekingAlpha

VTI ETF Daily Briefing: Key Information for Investors – November 7, 2025

Nov 07 2025TipRanks

CarMax Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday

Nov 07 2025Benzinga

Sangamo aims for Q1 2026 BLA filing for Fabry gene therapy as FDA confirms expedited process

Nov 06 2025SeekingAlpha

Sangamo (SGMO) Third Quarter 2025 Earnings Call Summary

Nov 06 2025NASDAQ.COM